Skip to main content

Table 1 Relative differences between algorithms and grid sizes for lung cancer patients

From: Dosimetric accuracy and clinical quality of Acuros XB and AAA dose calculation algorithm for stereotactic and conventional lung volumetric modulated arc therapy plans

 

Relative difference

p-value

Relative difference

p-value

(AXB2.5 -AAA2.5)/ AAA2.5×100%

 

(AXB1.0 - AXB2.5)/ AXB2.5×100%

 
 

Average ± SDV (min-max)

 

Average ± SDV (min-max)

 

Stage I (N = 8)

PTV

  D98%

−3.2% ± 4.0% (−12.3% – 0.5%)

0.06

0.7% ± 1.3% (−0.8% – 3.1%)

0.19

  D2%

0.2% ± 1.2% (−2.1% – 1.3%)

0.69

0.9% ± 0.4% (0.3% – 1.4%)

<0.01*

  Dmean

−0.6% ± 2.2% (−4.9% – 1.6%)

0.46

0.2% ± 0.5% (−0.6% – 1.2%)

0.45

Total lung

  V5Gy

1.3% ± 1.9% (−1.9% –3.2%)

0.12

0.1% ± 0.6% (−0.8% – 1.1%)

0.73

  V20Gy

2.0% ± 2.3% (0.0% – 5.7%)

0.05*

−0.7% ± 1.2% (−2.7% – 0.0%)

0.17

  MLD

0.0% ± 0.5% (−0.7% – 0.7%)

0.60

0.1% ± 0.2% (0.0% – 0.4%)

0.08

Time

  Calculation

−39.2% ± 13.5% (−50.3% – –8.2%)

<0.01*

304.7% ± 48.7% (226.9% – 345.8%)

<0.01*

Stage III (N = 7)

PTV

  D98%

−0.3% ± 0.7% (−0.8% – 1.3%)

0.33

0.2% ± 0.8% (−1.4% – 0.9%)

0.57

  D2%

−0.6% ± 2.0% (−2.1% – 3.0%)

0.47

0.6% ± 0.4% (−0.1% – 1.0%)

<0.01*

  Dmean

−0.8% ± 0.7% (−1.6% – 0.3%)

0.02*

0.1% ± 0.3% (−0.5% – 0.4%)

0.40

Total lung

  V5Gy

−1.8% ± 1.7% (−4.8% – 0.3%)

0.03*

−0.4% ± 0.7% (−1.5% – 0.4%)

0.16

  V20Gy

0.2% ± 0.7% (−0.5% – 1.5%)

0.69

0.0% ± 0.0% (0.0% –0.0%)

1.00

  MLD

−0.5% ± 0.6% (−1.3% – 0.0%)

0.09

0.2% ± 0.3% (0.0% – 0.6% )

0.17

Time

  Calculation

−31.4% ± 9.9% (−44.4% – –17.9%)

<0.01*

556.9% ± 91.1% (412.3% – 646.0%)

<0.01*

  1. *Significant relative difference tested by two-tailed student t-test.